Pfizer Inc. (NYSE:PFE) Stock Position Raised by Trivant Custom Portfolio Group LLC

Trivant Custom Portfolio Group LLC lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 100.0% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,200 shares of the biopharmaceutical company’s stock after buying an additional 600 shares during the period. Trivant Custom Portfolio Group LLC’s holdings in Pfizer were worth $33,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of PFE. Advisor OS LLC increased its stake in shares of Pfizer by 1.0% in the fourth quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock valued at $1,013,000 after purchasing an additional 365 shares during the period. Safeguard Investment Advisory Group LLC increased its stake in shares of Pfizer by 3.9% in the fourth quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock valued at $288,000 after purchasing an additional 371 shares during the period. Lantz Financial LLC increased its stake in shares of Pfizer by 1.3% in the first quarter. Lantz Financial LLC now owns 30,582 shares of the biopharmaceutical company’s stock valued at $849,000 after purchasing an additional 381 shares during the period. King Wealth Management Group increased its stake in shares of Pfizer by 2.4% in the fourth quarter. King Wealth Management Group now owns 16,686 shares of the biopharmaceutical company’s stock valued at $480,000 after purchasing an additional 388 shares during the period. Finally, Advance Capital Management Inc. increased its stake in shares of Pfizer by 4.0% in the fourth quarter. Advance Capital Management Inc. now owns 10,177 shares of the biopharmaceutical company’s stock valued at $293,000 after purchasing an additional 391 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 0.6 %

Shares of NYSE:PFE opened at $27.98 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. The company has a market cap of $158.55 billion, a PE ratio of -466.26, a price-to-earnings-growth ratio of 1.10 and a beta of 0.70. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $37.80. The firm has a 50 day simple moving average of $27.90 and a 200 day simple moving average of $27.68.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, beating the consensus estimate of $0.56 by $0.26. The business had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The firm’s quarterly revenue was down 19.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.23 EPS. As a group, research analysts expect that Pfizer Inc. will post 2.38 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be given a $0.42 dividend. The ex-dividend date is Thursday, July 25th. This represents a $1.68 annualized dividend and a dividend yield of 6.00%. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. BMO Capital Markets reiterated an “outperform” rating and issued a $36.00 price objective (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Morgan Stanley increased their price objective on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Wednesday. Finally, Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Nine equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, Pfizer currently has an average rating of “Hold” and an average target price of $35.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.